AMPLIPHI BIOSCIENCES CORP COM PAR APHB: NYSE American
AMPLIPHI BIOSCIENCES CORP COM PAR APHB: NYSE American AmpliPhi Biosciences Announces Presentation of Bacteriophage Therapy Case Study at ISHLT Annual Meeting
Investors love biotech stocks for a chance of massive returns those can offer if a company strikes excellent news. Case in point is APHB stock. The biotechnology firm announced positive topline results for the first seven patients treated under its ongoing single-patient expanded access program. Six of the seven patients (86%) achieved treatment success (physician’s assessment), defined as complete resolution or significant improvement of baseline signs and symptoms. All patients were severely ill and unresponsive to antibiotic treatment at the time of enrollment on last Jan. Next week AmpliPhi Biosciences Corporation (NYSE American: APHB) will announce the presentation of a case study of a lung transplant recipient suffering from a resistant Pseudomonas aeruginosa lung infection who received treatment with bacteriophage therapeutics, including AB-PA01. The data will be presented at the International Society for Heart and Lung Transplantation 38(the) Annual Meeting and Scientific Sessions, being held April 11-14, 2018 in Nice, France. We think this stock could attract more investors and My rate about it is Strong hold /Buy and the possible price target for the next ten days could be 1.60 $.
If you would like to know what we think about ATNM stock the possible next nova for this month, please Join our mail list.
Important note: We are just a small team of independent traders and uncertified technical chart analysis, and we do not have any insider trading or connection with any company related to any stocks we mentioned. You own your decision to buy, hold or sell any of them. DISCLAIMER: As an investor, you know that any kind of investment opportunity has its risks. There is no such thing as low risk stocks and we recommend you invest wisely. Investing in Stocks is highly speculative. All of the content on our website and in our email alerts is for informational purposes only, and should not be construed as an offer, or solicitation of an offer, to buy or sell securities.
Share on Facebook
Share on Twitter
I'm busy working on my blog posts. Watch this space!